Umberto Dianzani
Overview
Explore the profile of Umberto Dianzani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
156
Citations
2695
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Costa F, Beltrami E, Mellone S, Sacchetti S, Boggio E, Gigliotti C, et al.
Biomedicines
. 2023 May;
11(4).
PMID: 37189745
Monogenic autoimmune disorders represent an important tool to understand the mechanisms behind central and peripheral immune tolerance. Multiple factors, both genetic and environmental, are known to be involved in the...
12.
Boggio E, Gigliotti C, Stoppa I, Pantham D, Sacchetti S, Rolla R, et al.
Pharmaceutics
. 2023 Mar;
15(3).
PMID: 36986798
The most important limitations of chemotherapeutic agents are severe side effects and the development of multi-drug resistance. Recently, the clinical successes achieved with immunotherapy have revolutionized the treatment of several...
13.
Batoni E, Bonatti A, De Maria C, Dalgarno K, Naseem R, Dianzani U, et al.
Pharmaceutics
. 2023 Mar;
15(3).
PMID: 36986675
This work presents a computational model to study the degradation behavior of polyester-based three-dimensional (3D) functionalized scaffolds for bone regeneration. As a case study, we investigated the behavior of a...
14.
Puricelli C, Boggio E, Gigliotti C, Stoppa I, Sutti S, Giordano M, et al.
Int J Mol Sci
. 2023 Mar;
24(5).
PMID: 36901997
Platelets, traditionally known for their roles in hemostasis and coagulation, are the most prevalent blood component after erythrocytes (150,000-400,000 platelets/μL in healthy humans). However, only 10,000 platelets/μL are needed for...
15.
Gigliotti C, Dianzani C, Stoppa I, Monge C, Sutti S, Sblattero D, et al.
Int J Mol Sci
. 2023 Feb;
24(3).
PMID: 36769276
Activated T cells express the inducible T-cell co-stimulator (ICOS) that, upon binding to its ubiquitously expressed ligand (ICOSL), regulates the immune response and tissue repair. We sought to determine the...
16.
Cannito S, Dianzani U, Parola M, Albano E, Sutti S
Biosci Rep
. 2023 Jan;
43(1).
PMID: 36691794
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death worldwide. In the recent years nonalcoholic fatty liver disease (NAFLD) is becoming a growing cause of HCCs and the...
17.
Banche-Niclot F, Corvaglia I, Cavalera C, Boggio E, Gigliotti C, Dianzani U, et al.
Biomolecules
. 2023 Jan;
13(1).
PMID: 36671479
Vertebral compression fractures are typical of osteoporosis and their treatment can require the injection of a cement through a minimally invasive procedure to restore vertebral body height. This study reports...
18.
Monge C, Stoppa I, Ferraris C, Bozza A, Battaglia L, Cangemi L, et al.
Nanomaterials (Basel)
. 2022 Dec;
12(23).
PMID: 36500861
High-grade melanoma remains a major life-threatening illness despite the improvement in therapeutic control that has been achieved by means of targeted therapies and immunotherapies in recent years. This work presents...
19.
Melo P, Montalbano G, Boggio E, Gigliotti C, Dianzani C, Dianzani U, et al.
Polymers (Basel)
. 2022 Sep;
14(18).
PMID: 36145925
The treatment of osteoporotic fractures is a severe clinical issue, especially in cases where low support is provided, e.g., pelvis. New treatments aim to stimulate bone formation in compromised scenarios...
20.
Puricelli C, Boggio E, Gigliotti C, Stoppa I, Sutti S, Rolla R, et al.
Pharmaceutics
. 2022 Sep;
14(9).
PMID: 36145531
Conventional therapies for immune-mediated diseases, including autoimmune disorders, transplant reactions, and allergies, have undergone a radical evolution in the last few decades; however, they are still not specific enough to...